COVAX
COVID-19 Vaccines Global Access, abbreviated as COVAX, was a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations, and the World Health Organization, alongside key delivery partner UNICEF. It was one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinated international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF was the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery.
By 19 October 2020, 184 countries had joined COVAX.
COVAX began distributing vaccines in February 2021. Though COVAX promised 100 million doses by the end of March, this goal was not reached until 6 July. By mid-August 2021, COVAX delivered 200 million vaccine doses to nearly 140 countries instead of the 600 million doses initially projected. The continued shortage of COVID-19 vaccines delivered through COVAX is blamed on "vaccine nationalism" by richer nations, and the diversion of 400 million Oxford–AstraZeneca COVID-19 vaccine doses, produced under license by the Serum Institute of India, for domestic use in India. As of April 2022, more than 1.4 billion doses were delivered, when the largest recipients were Bangladesh, Pakistan and Indonesia.
History
In April 2020 the World Health Organization, the European Commission, and the government of France founded the Access to COVID-19 Tools Accelerator, an initiative begun as a response to the COVID-19 pandemic. COVID-19 Vaccines Global Access is one of its four pillars. It is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations, and the WHO, alongside key delivery partner UNICEF.COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines.
A financing instrument called the COVID-19 Vaccines Advance Market Commitment was presented to prospective donors at the Gavi COVAX AMC 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on 15 April 2021. The virtual event was hosted by GAVI board chair José Manuel Barroso, U.S. Secretary of State Antony Blinken, and acting United States Agency for International Development Administrator Gloria Steele. Among the attendees were heads of state, corporate leaders and representatives from global nonprofit organizations. The program was fully launched by GAVI at the Global Vaccine Summit on 4 June 2021.
Vaccine candidates
As of 23 December 2021, the WHO had approved Oxford–AstraZeneca, Pfizer–BioNTech, Moderna, Sinopharm BIBP, CoronaVac, Janssen, Covaxin, and Novavax vaccines for emergency use.These vaccines can be distributed as part of COVAX per decision in May 2021.
Many of the countries benefitting from COVAX have "limited regulatory capacity" and depend on WHO's authorisations. By early 2021, WHO was reviewing 11 potential COVID-19 vaccines for its Emergency Use Listing. The first vaccine WHO authorised for its EUL on 31 December 2020 was the Pfizer–BioNTech COVID-19 vaccine—an RNA vaccine developed by the German company BioNTech in cooperation with the American company Pfizer sold under the brand name Comirnaty.
On 24 August 2020 WHO stated that COVAX had nine CEPI-supported vaccine candidates and nine candidates undergoing trials, giving it the largest selection of COVID-19 vaccinations in the world. By December 2020, COVAX had finalized negotiations with other manufacturers that gave it access to two billion vaccine doses.
Distribution (recipients)
COVAX provides vaccines to the developing world. A total of 92 low- and middle-income countries are eligible to receive COVID-19 vaccines through the COVAX mechanism through the COVAX Vaccines Advance Market Commitment financing instrument. COVAX AMC is funded by donor contributions. COVAX AMC funds the COVAX Facility, the vaccine procurement platform.On 3 February 2021, GAVI, the WHO, and UNICEF published the country-by-country distribution of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines forecast for first half of 2021. The early projection includes 336 million doses of the Oxford–AstraZeneca vaccine as well as 1.2 million doses of the Pfizer–BioNTech vaccine to the 145 COVAX facility participants. It is expected that health care workers and the most vulnerable will receive the first doses, which are anticipated to reach approximately 3.3% of the total population of each participating country by the end of the first half of 2021.
In February 2021, the WHO and Chubb Limited announced the roll out of a no-fault compensation scheme for COVID-19 vaccinations for low and middle-income countries which would be financed initially through Gavi COVAX AMC donor funding.
On 24 February 2021, Ghana became the first country in the world to receive vaccines through COVAX when 600,000 doses of the Oxford–AstraZeneca vaccine were delivered to Accra. On 2 March, COVID-19 vaccines were being distributed in Ghana by Zipline drones. This method allows reaching remote areas.
On 1 March 2021, frontline workers and public officials from the Ivory Coast became the first persons to be inoculated with COVID-19 vaccines shipped from the COVAX Facility. More than 500,000 doses of the Oxford–AstraZeneca COVID-19 vaccine manufactured by the Serum Institute of India were shipped to the city of Abidjan the week before. The vaccines were flown in by UNICEF from Mumbai.
On 5 March 2021, Moldova received 14,400 Oxford–AstraZeneca COVID-19 vaccine units through COVAX, becoming the first European country to do so. The country had already been donated 21,600 doses of the same vaccine by Romania some days earlier.
On 25 March 2021, Bosnia and Herzegovina received 24,300 Pfizer–BioNTech and 26,400 Oxford–AstraZeneca COVID-19 vaccine units through COVAX, becoming the second European country to do so. The country had already been, in total, donated over 20,000 doses of the Oxford–AstraZeneca vaccine by Serbia and Slovenia some weeks earlier.
On 8 June 2021, Uruguay released health data from their vaccination efforts through the COVAX program. Almost 800,000 individuals or 52% of the adult population received two doses of the CoronaVac or Pfizer vaccines. The government also studied the effectiveness of the Pfizer/BioNTech vaccine among 162,047 health workers and people over 80 years old. Both vaccine types reduced hospitalisations and deaths by over 90%, and infection rates by more than 60%. Because of accessible healthcare and available COVAX vaccine supplies, the small Latin nation was able to ward off a serious COVID-19 spike in May 2021.
On 1 August 2021, the Venezuelan government announced it will receive 6.2 million doses of coronavirus vaccines through the COVAX initiative. Part of the payment to the GAVI alliance was first blocked due to economic sanctions. Venezuela is a self-financing participant of COVAX. According to the Pan-American Health Organization, Venezuela received China's Sinopharm BIBP vaccine and CoronaVac.
According to a report produced by the People's Vaccine Alliance covering 14 countries, 'vaccine hesitancy' was not the reason for low jab rates in low- and middle-income countries. But the report found that a lack of testing capacity, sufficient vaccine doses and refrigerated storage were mostly to blame for the low vaccination rates. Poor information policies on vaccine distribution and underfunded healthcare systems were also mentioned. The Vaccine Alliance found that "systemic racism has plagued the global response to Covid-19".
| Participant | SFP/AMC | AstraZeneca SII | AstraZeneca SK Bioscience | Pfizer–BioNTech | Total |
 IndiaParticipants (donors)COVAX is principally funded by Western countries. As of 19 February 2021, 30 countries have signed commitment agreements to the COVAX Facility as well as the European Union. Although more than $6 billion was pledged, not all of the funding has been delivered yet. In April, the initiative wrote that it had not yet received its target of $3.2 billion for 2021.Although mainly funded by governments, the COVAX scheme is also funded by private-sector and philanthropic contributions, and recipient countries may share some costs for vaccines and delivery. In May 2021, UNICEF made an urgent appeal to industrialised nations to pool their excess COVID-19 vaccine capacity to make up for a 125-million-dose gap in the COVAX program. Only a limited amount of vaccines are distributed efficiently, and the shortfall of vaccines in South America and parts of Asia are due to a lack of expedient donations by richer nations. International organisations have pointed at Nepal, Sri Lanka, and Maldives as well as Argentina and Brazil, and some parts of the Caribbean as problem areas, where vaccines are in short supply. UNICEF has also been critical towards proposed donations of Moderna and Pfizer vaccines since these are not slated for delivery until the second half of 2021, or early 2022.
|
United